Immunoprophylaxis

Avaxim^®

AVAXIM^® is indicated for active immunization against infection caused by hepatitis A virus (HAV) in persons 12 years of age and older. AVAXIM^® can be used for primary immunization or as a booster following primary immunization with AVAXIM® or other similar hepatitis A vaccines.

Beyfortus^®

Beyfortus^® (nirsevimab injection) is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in:¹

• Neonates and infants during their first RSV season
• Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season, which may include but is not limited to children with:
  • Chronic lung disease of prematurity (CLD)
  • Hemodynamically significant congenital heart disease (CHD)
  • Immunocompromised states 
  • Down syndrome
  • Cystic fibrosis
  • Neuromuscular disease
  • Congenital airway anomalies

IMOVAX^®

IMOVAX^® Rabies is indicated for the active immunization of individuals of all age groups to prevent disease caused by the rabies virus. It is indicated for both pre-exposure prophylaxis and post-exposure prophylaxis. IMOVAX^® Rabies should be used in accordance with official recommendations. 

MenQuadfi^®

MenQuadfi^® is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y in individuals 12 months of age and older. MenQuadfi does not prevent N. meningitidis serogroup B disease.

TYPHIM Vi^®

TYPHIM Vi^® is indicated for active immunization against S. typhi, the organism which causes typhoid fever.⁷

TYPHIM Vi^® is recommended for active immunization in persons 2 years of age and older, in the following situations:

1. Travellers to endemic or epidemic areas or where sanitary conditions may be doubtful and where travellers may be exposed to potentially contaminated food and water, particularly when prolonged exposure is anticipated.
2. Travellers with reduced or absent gastric acid secretion.
3. People with ongoing household or intimate exposure to an S. typhi carrier.
4. Laboratory workers who frequently handle cultures of S. typhi.

YF-VAX^®

YF-VAX^® is indicated for active immunization for the prevention of yellow fever in persons 9 months of age or older. It is indicated for both primary and booster vaccination.

Yellow fever vaccination is advised for travellers passing through or living in countries in Africa, Central America and South America where yellow fever infection is officially reported. It is also recommended for travel outside of urban areas of countries that do not officially report yellow fever but lie in the yellow fever "endemic zones".

Consult the respective product monographs (listed above) for important information on indications and clinical use, contraindications, warnings, precautions, adverse reactions, drug interactions, dosing, and administration. These product monographs are also available through our medical department at 1-888-852-6887.